Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

First Patient Dosed in VIRAGE, a Ph 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

February 1, 2023

First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

February 1, 2023

Randomization in PNT2002’s Ph 3 SPLASH Trial Completed

January 17, 2023

First patient dosed with B4t2-001 CAR-T targeting solid tumors

January 17, 2023

Additional Patients dosed in Ongoing Ph 1b/2a IMX-110 Monotherapy Clinical Trial

January 17, 2023

Enrollment in Ph 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate completed

January 17, 2023

Enrollment in Ph 2 Clinical Trial MN-166 (ibudilast) trial in Recurrent and Newly Diagnosed Glioblastoma patients completed

January 17, 2023

Enrollment Completed in the Global Registrational Ph 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer

January 11, 2023

50% Enrollment completed in Randomised Ph IIb TACTI-003 Trial for 1L Head & Neck Cancer

January 11, 2023

First Patient Dosed in PRESERVE-004, a Ph 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® in Patients with Platinum-Resistant Ovarian Cancer

January 11, 2023

First Patient Dosed in the Ph 2 U.S. Study of CTX-009 in Patients with mCRC

January 11, 2023

Patient dosing stopped in MGTA-117 Ph 1/2 Dose Escalation Trial in R/R AML and MDS

January 4, 2023

First Patient Dosed in PRESERVE-004 Ph 2 Clinical Trial of ONC-392 + KEYTRUDA® in Patients with Platinum-Resistant Ovarian Cancer

January 4, 2023

CYAD-211 CAR-T program to be discontinued

January 4, 2023

Safety Review Committee Approves to Proceed to Final Cohort in Acclaim-1 Ph 1 Dose Escalation Trial of REQORSA® + Tagrisso® in Advanced NSCLC

December 19, 2022

FDA Lifts Clinical Hold on the Investigational New Drug Application for BEAM-201

December 13, 2022

First Patient Dosed in Ph 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

December 13, 2022

Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting announced

December 13, 2022

Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

December 13, 2022

Ph 1 Trial of E6201 + Dabrafenib initiated in Patients with CNS Metastases from BRAF V600 Mutated Metastatic Melanoma

December 5, 2022

SAPPHIRE Ph 3 study of sitravatinib + nivolumab in patients with chemo- and IO-resistant 2L/3L NSQ-NSCLC will continue to the study’s final analysis

December 5, 2022

First Patient Dosed in Ph 2 ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy

November 30, 2022

Positive Update On Joint TIGIT Program From Interim Analysis Of ARC-7 Study In NSCLC Announced

November 30, 2022

Ph 3 trial of SYK inhibitor, entospletinib, for the treatment of newly diagnosed patients with NPM1-mutated AML to be discontinued

November 16, 2022

First Patient Dosed in Ph 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

November 16, 2022
Page1 … Page19 Page20 Page21 Page22 Page23

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.